Fig. 5
From: Microbiota-derived urolithin A in monoclonal gammopathies and multiple myeloma therapy
A Bioluminescence analysis in dorsal and ventral position of the urolithin A (UroA)-treated group and the control group exposed to DMSO, after 7, 14, 21, and 28 days from the start of the experiment. B Comparison of the luminescent signal between the control and UroA-treated groups at days 7, 14, and 21. The mean ± SEM luminescent signal obtained in photons per second (f/s) is plotted. C Kaplan–Meier survival analysis of the control and UroA-treated groups. **P ≤ 0.01